Metformin: An old drug with new potential

Expert Opinion on Investigational Drugs

Volumn 22, Issue 12, 2013, Pages 1511-1517

  Hajjar, Joud ^a   Habra, Mouhammed Amir ^b   Naing, Aung ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cancer; Diabetes; HIV; Metformin

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; BIGUANIDE; GLUCOSE; INSULIN; METFORMIN; MULTIDRUG RESISTANCE PROTEIN 1; PHENFORMIN; PROGESTERONE RECEPTOR; SULFONYLUREA;

ACNE; ADIPOSE TISSUE; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLOATING; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CELL PROLIFERATION; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DIARRHEA; DRUG TARGETING; ENDOMETRIUM CANCER; ENZYME ACTIVATION; FATTY ACID OXIDATION; FATTY LIVER; FIBRINOLYSIS; FLATULENCE; GENETIC TRANSCRIPTION; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; HEART PROTECTION; HIRSUTISM; HUMAN; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN SENSITIVITY; INSULIN TREATMENT; KIDNEY FUNCTION; LACTIC ACIDOSIS; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; METALLIC TASTE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OFF LABEL DRUG USE; OVARY POLYCYSTIC DISEASE; PROSTATE CANCER; REVIEW; RNA TRANSLATION; SIDE EFFECT; THROMBOCYTE AGGREGATION; TUBEROUS SCLEROSIS; VOMITING; WEIGHT GAIN;

ANIMALS; ANTINEOPLASTIC AGENTS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; NEOPLASMS;

EID: 84887714424     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2013.833604     Document Type: Review

References (66)

1. Bailey CJ, Day C. Traditional plant medicines as treatments for diabetes. Diabetes Care 1989;12:553-64
2. Dowling RJ, Zakikhani M, Fantus IG, et al. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 2007;67:10804-12
3. Witters LA. The blooming of the French lilac. J Clin Invest 2001;108:1105-7
4. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996;334:574-9
5. Bailey CJ, Day C. Metformin: Its botanical background. Pract Diabetes Int 2004;21:115-17
6. Graham GG, Punt J, Arora M, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 2011;50:81-98
7. Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 1996;30:359-71
8. Cowie CC, Rust KF, Ford ES, et al. Full accounting of diabetes and pre-diabetes in the US population in 1988-1994 and 2005-2006. Diabetes Care 2009;32:287-94
9. Williamson DF, Cowie CC. Diabetes risk reduction behaviors among US adults with prediabetes. Am J Prev Med 2010;38:403-9
10. Cowie CC, Rust KF, Byrd-Holt DD, et al. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: national Health And Nutrition Examination Survey 1999-2002. Diabetes Care 2006;29:1263-8
11. Center for Disease Control, Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. US Department of Health and Human Services; 2011
12. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403
13. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65. This manuscript discussed the effects of metformin in reducing complications in overweight patients with type 2 diabetes.
14. Kooy A, de Jager J, Lehert P, et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med 2009;169:616-25
15. Hung AM, Roumie CL, Greevy RA, et al. Kidney function decline in metformin versus sulfonylurea initiators: Assessment of time-dependent contribution of weight, blood pressure, and glycemic control. Pharmacoepidemiol Drug Saf 2013; [Epub ahead of print]
16. Wright AD, Cull CA, Macleod KM, et al. Hypoglycemia in Type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS73. J Diabetes Complications 2006;20:395-401
17. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001;108:1167-74
18. Foretz M, Hebrard S, Leclerc J, et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest 2010;120:2355-69
19. Batandier C, Guigas B, Detaille D, et al. The ROS production induced by a reverse-electron flux at respiratory-chain complex 1 is hampered by metformin. J Bioenerg Biomembr 2006;38:33-42
20. Mannucci E, Ognibene A, Cremasco F, et al. Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care 2001;24:489-94. This manuscript discussed the impact of metformin on GLP-1 and leptin levels in obese nondiabetic subjects.
21. Mulherin AJ, Oh AH, Kim H, et al. Mechanisms underlying metformin-induced secretion of glucagon-like peptide-1 from the intestinal L cell. Endocrinology 2011;152:4610-19
22. Miller RA, Chu Q, Xie J, et al. Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature 2013;494:256-60
23. Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 2003;327:951-3
24. Badr D, Kurban M, Abbas O. Metformin in dermatology: An overview. J Eur Acad Dermatol Venereol 2013; [Epub ahead of print]
25. Pryor PR, Liu S, Clark AE, et al. Chronic insulin effects on insulin signalling and GLUT4 endocytosis are reversed by metformin. Biochem J 2000;348:83
26. Carvajal R, Rosas C, Kohan K, et al. Metformin augments the levels of molecules that regulate the expression of the insulin-dependent glucose transporter GLUT4 in the endometria of hyperinsulinemic PCOS patients. Hum Reprod 2013; [Epub ahead of print]
27. Schwimmer J, Middleton M, Deutsch R, et al. A phase 2 clinical trial of metformin as a treatment for nondiabetic paediatric non alcoholic steatohepatitis. Aliment Pharmacol Ther 2005;21:871-9
28. Loomba R, Lutchman G, Kleiner DE, et al. Clinical trial: Pilot study of metformin for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2009;29:172-82
29. Uygun A, Kadayifci A, Isik AT, et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2004;19:537-44. This manuscript discussed the treatment of NASH with metformin.
30. Rena G, Pearson ER, Sakamoto K. Molecular mechanism of action of metformin: old or new insights Diabetologia 2013;56(9):1898-906
31. Hadigan C, Corcoran C, Basgoz N, et al. Metformin in the treatment of HIV lipodystrophy syndrome. JAMA 2000;284:472-7
32. Driscoll SD, Meininger GE, Lareau MT, et al. Effects of exercise training and metformin on body composition and cardiovascular indices in HIV-infected patients. AIDS 2004;18:465-73
33. Kohli R, Shevitz A, Gorbach S, et al. A randomized placebo-controlled trial of metformin for the treatment of HIV lipodystrophy. HIV Med 2007;8:420-6
34. Hollenbeck CB, Johnston P, Varasteh BB, et al. Effects of metformin on glucose, insulin and lipid metabolism in patients with mild hypertriglyceridaemia and non-insulin dependent diabetes by glucose tolerance test criteria. Diabete Metab 1991;17:483-9
35. Juhan-Vague I, Valadier J, Alessi M, et al. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis. Thromb Haemost 1987;57:67
36. Tremoli E, Ghiselli G, Maderna P, et al. Metformin reduces platelet hypersensitivity in hypercholesterolemic rabbits. Atherosclerosis 1982;41:53-60
37. Verma S, Yao L, Dumont AS, et al. Metformin treatment corrects vascular insulin resistance in hypertension. J Hypertens 2000;18:1445-50
38. Petersen JS, DiBona GF. Acute sympathoinhibitory actions of metformin in spontaneously hypertensive rats. Hypertension 1996;27:619-25
39. Dancey JE. Agents targeting ras signaling pathway. Curr Pharm Des 2002;8:2259-67
40. Zakikhani M, Dowling R, Fantus IG, et al. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006;66:10269-73.. This manuscript highlighted metformin as an AMPK-dependent growth inhibitor.
41. Vázquez-Mart́n A, Oliveras-Ferraros C, del Barco S, et al. mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb). Clin Transl Oncol 2009;11:455-9
42. Rozengurt E, Sinnett-Smith J, Kisfalvi K. Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: A novel target for the antidiabetic drug metformin in pancreatic cancer. Clin Cancer Res 2010;16:2505-11
43. Goodwin PJ, Ligibel JA, Stambolic V. Metformin in breast cancer: Time for action. J Clin Oncol 2009;27:3271-3
44. Alimova IN, Liu B, Fan Z, et al. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 2009;8:909-15
45. Deng L, Lin-Lee Y-C, Claret F-X, et al. 2-Acetylaminofluorene Up-regulates Rat mdr1bExpression through generating reactive oxygen species that activate NF-kB pathway. J Biol Chem 2001;276:413-20
46. Kim HG, Hien TT, Han EH, et al. Metformin inhibits P-glycoprotein expression via the NFkB pathway and CRE transcriptional activity through AMPK activation. Br J Pharmacol 2011;162:1096-108
47. Anastasiou D. Metformin: A case of divide and conquer. Breast Cancer Res 2013;15:1-3
48. Zakikhani M, Dowling RJ, Sonenberg N, et al. The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res (Phila) 2008;1:369-75
49. Buzzai M, Jones RG, Amaravadi RK, et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 2007;67:6745-52
50. Duo J, Ma Y, Wang G, et al. Metformin synergistically enhances antitumor activity of histone deacetylase inhibitor trichostatin a against osteosarcoma cell line. DNA and Cell Biology 2013;32(4):156-64
51. Shackelford DB, Abt E, Gerken L, et al. LKB1 Inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. Cancer Cell 2013;23(2):143-58
52. Libby G, Donnelly LA, Donnan PT, et al. New users of metformin are at low risk of incident cancer: A cohort study among people with type 2 diabetes. Diabetes Care 2009;32:1620-5
53. Dowling RJ, Niraula S, Stambolic V, et al. Metformin in cancer: Translational challenges. J Mol Endocrinol 2012;48:R31-43.. This manuscript described the translational challenges regarding metformin in the treatment of cancer.
54. Evans JM, Donnelly LA, Emslie-Smith AM, et al. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005;330:1304-5
55. Jiralerspong S, Palla SL, Giordano SH, et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 2009;27:3297-302
56. Zhang X, Shu L, Hosoi H, et al. Predominant nuclear localization of mammalian target of rapamycin in normal and malignant cells in culture. J Biol Chem 2002;277:28127-34
57. Dong L, Zhou Q, Zhang Z, et al. Metformin sensitizes endometrial cancer cells to chemotherapy by repressing glyoxalase I expression. J Obstet Gynaecol Res 2012;38:1077-85
58. Hanna RK, Zhou C, Malloy KM, et al. Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway. Gynecol Oncol 2012;125:458-69
59. Cantrell LA, Zhou C, Mendivil A, et al. Metformin is a potent inhibitor of endometrial cancer cell proliferation-implications for a novel treatment strategy. Gynecol Oncol 2010;116:92-8
60. Xie Y, Wang YL, Yu L, et al. Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells. J Steroid Biochem Mol Biol 2011;126:113-20
61. Phillips BB. Managing therapy and adverse effects with antihyperglycemic agents: A focus on metformin and acarbose. Pharm Pract Manag Q 1997;17:21-31
62. Greibe E, Miller JW, Foutouhi SH, et al. Metformin increases liver accumulation of vitamin B12-An experimental study in rats. Biochimie 2013;95:1062-5
63. Misbin RI, Green L, Stadel BV, et al. Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med 1998;338:265-6
64. Salpeter S, Greyber E, Pasternak G, et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2006;CD002967
65. Sulkin TV, Bosman D, Krentz AJ. Contraindications to metformin therapy in patients with NIDDM. Diabetes Care 1997;20:925-8
66. Jones GC, Macklin JP, Alexander WD. Contraindications to the use of metformin. BMJ 2003;326:4-5